StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock analysis

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.83−6.12 (-4.67%)

Close on Nov 16, 2026Market cap $8.08BP/E 121.2Yield –

StockData Score

Prices as of Nov 16, 2026How the score works

Value0Growth2Performance4Health6Dividend0

Mixed12 of 30 checks passed

Protagonist Therapeutics passes 12 of the 30 checks behind our score; 10 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
4/6
Financial health
6/6
Dividend
0/6

What stands out

  • Return on capital over 10%

    Return on invested capital was 73.3%, above the 10% that usually covers the cost of capital.

  • No debt

    Protagonist Therapeutics has no borrowings on its latest balance sheet.

  • Revenue growing 10%+ a year

    Revenue grew 20.1% a year over the last three fiscal years.

  • Interest well covered

    No meaningful interest expense to cover.

What to watch

  • Margin of safety under 20%

    The price is 199% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $124.83 is above our fair value estimate of $41.72.

  • Return on equity under 15%

    Return on equity was 11.0% over the last twelve months and averaged -17.4% over five years; we look for 15% on both.

  • P/E above its 5-year median

    Protagonist Therapeutics's P/E of 121.2 is above its own 5-year median of 60.9.

Valuation0/6
  • P/E above its 5-year median

    Protagonist Therapeutics's P/E of 121.2 is above its own 5-year median of 60.9.

  • P/E above the industry

    Protagonist Therapeutics's P/E of 121.2 is above the Drugs median of 22.0.

  • EV/EBITDA above its 5-year median

    Protagonist Therapeutics's EV/EBITDA of 121.8 is above its 5-year median of 80.3.

  • P/B above the industry

    Protagonist Therapeutics's price-to-book of 9.60 is above the Drugs median of 2.10.

  • Trading above fair value

    The share price of $124.83 is above our fair value estimate of $41.72.

  • Margin of safety under 20%

    The price is 199% above fair value, so there is no margin of safety.

Growth2/6
  • Revenue growing 10%+ a year

    Revenue grew 20.1% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 34.8% over the last twelve months; the Drugs median is 6.5%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance4/6
  • Return on equity under 15%

    Return on equity was 11.0% over the last twelve months and averaged -17.4% over five years; we look for 15% on both.

  • Return on capital over 10%

    Return on invested capital was 73.3%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Protagonist Therapeutics's return on equity of 11.0% is above the Drugs median of -59.1%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was 29.4% over the last twelve months, against a 5-year average of -258%.

  • Net margin above the industry

    Protagonist Therapeutics's net margin of 29.4% is above the Drugs median of -59.9%.

Financial health6/6
  • No debt

    Protagonist Therapeutics has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 21.71 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 111.24; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6
  • No dividend

    Protagonist Therapeutics has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Our estimate per share

$41.72

The share price is 199% above this estimate.

20%+ below
Near fair value
20%+ above
$124.83Price$41.72Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E41.6×60.9×22.0×$42.8247%
EV/EBITDA30.0×80.3×16.9×$39.8641%
P/B3.4×4.6×2.1×$43.7912%
Earnings powerleft out, too far from the others8.1% cost of equity––$10.76–
Fair value$41.72100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 60.9
  • Drugs median 22.0

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$93.00M
Value traded per 1% price move
$53.07M

Downside

Low risk

Typical loss in a bad month
10.4%
Volatility (annualized)
40%
Sharpe ratio, 1 year
1.12
Beta to the S&P 500 (5Y)
0.59

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2013 to 2025

Operating margin

-343.6%−118.3 pts over 5 years

Net margin

-282.8%−51.8 pts over 5 years

See a number that looks wrong?